Diversify Advisory Services LLC Has $2.91 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Diversify Advisory Services LLC grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 16.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,773 shares of the pharmaceutical company's stock after acquiring an additional 827 shares during the quarter. Diversify Advisory Services LLC's holdings in Vertex Pharmaceuticals were worth $2,906,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Mascagni Wealth Management Inc. acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth approximately $31,000. Mpwm Advisory Solutions LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth approximately $40,000. Minot DeBlois Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $44,000. Prestige Wealth Management Group LLC grew its position in shares of Vertex Pharmaceuticals by 45.5% in the fourth quarter. Prestige Wealth Management Group LLC now owns 112 shares of the pharmaceutical company's stock valued at $45,000 after purchasing an additional 35 shares during the last quarter. Finally, SJS Investment Consulting Inc. grew its position in shares of Vertex Pharmaceuticals by 46.2% in the first quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock valued at $46,000 after purchasing an additional 30 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

VRTX has been the topic of several research reports. Bank of America upped their target price on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research report on Monday, March 31st. Royal Bank Of Canada set a $420.00 target price on Vertex Pharmaceuticals and gave the company a "sector perform" rating in a research report on Tuesday, June 17th. Needham & Company LLC reaffirmed a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Leerink Partnrs downgraded Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $535.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $511.71.

Vertex Pharmaceuticals Trading Down 0.7%

NASDAQ VRTX traded down $3.46 on Friday, reaching $459.81. The company had a trading volume of 975,143 shares, compared to its average volume of 1,420,625. The firm has a market cap of $118.08 billion, a price-to-earnings ratio of -117.30 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The business has a 50 day moving average of $449.49 and a two-hundred day moving average of $462.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The business's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.76 earnings per share. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.